influenza virus remain signifies public health threat despite into vaccine antivirus drug major limit current vaccine therapy pathogen diver genre shift drift simply costeffect passive immune strategy via vivo product crossprotect antibody molecule may augment exist season tandem outbreak engine synthetic plasmid dna encode two novel broadly monoclonal antibody target b until enhance delivery dnaencod dab construct show induce robust level function direct virus mouse serum mouse receive single incl antiinfluenza survive lethal group h challenge yield protect victoria yamagata linear morbid mortal furthermore dab deli coord result except broad demons similar achieve convent protein warrant investing immune therapy platform distinct advantage sustain immunoprophylaxi 